DOI: http://dx.doi.org/10.18203/2349-2902.isj20202042

A cross-sectional study on the pattern of recurrence in carcinoma breast patients based on molecular subtypes

Nitheesh Chalil, Induchoodan Ponnamma Pillai Sukumaran Nair, Nizarudeen Aliyarukunju, Abdul Latheef

Abstract


Background: Breast cancer is a major public health issue and it is the leading cause of cancer related death in females worldwide. New insights in the cancer treatment led to considerable improvement in the survival of cancer patients. But metastasis remain an area were all sorts of conventional treatments fails and it is the cause of death of most carcinoma breast patients. In this study we aim to establish a possible link to local recurrence and distant metastasis with different biological subtypes of breast cancer.

Methods: One hundred and eighty patients of carcinoma breast patients of carcinoma breast who presented with local recurrence or distant metastasis in the period of January 2018 to March 2019 in Government Medical College, Thiruvananthapuram were included in this study. These data were collected from the hospital records.

Results: Local recurrence was most seen in triple negative (50%) subtype followed by HER2 (32.1%) enriched. Local recurrence was least among luminal A (13.8%) with a p value of 0.001. Bone metastasis was the most common type of metastasis and was most seen in luminal A (p=0.001). Triple negative had the maximum CNS metastasis with a p value of 0.003. Liver metastasis was seen mostly in luminal B (26.2%) and A (20.7%) and lung metastasis in triple negative (13.5%) and HER2/neu (10.7%). However, there was no significant association for lung or liver metastasis to any subtype.

Conclusions: Biological subtypes of breast cancer classified by immunohistochemical expression of ER, PR, HER2, Ki 67 show different clinicopathological features, recurrence pattern, and survival outcomes.


Keywords


Carcinoma breast, Biological subtypes, Local recurrence, Metastasis, Triple negative, HER2

Full Text:

PDF

References


Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363-85.

Retief FP, Cilliers L. Breast cancer in antiquity. S Afr Med J. 2011;101(8):513-5.

Sakorafas GH, Safioleas M. Breast cancer surgery: an historical narrative. Part I. From prehistoric times to Renaissance. Eur J Cancer Care (Engl). 2009;18(6):530-44.

Halsted CP, Benson JR, Jatoi I. A historical account of breast cancer surgery: beware of local recurrence but be not radical. Future Oncol. 2014;10(9):1649-57.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74.

Perou CM, Sorlie T, Eisen MB, Rijn VDM, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24(2):157-67.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74.

Cardoso F, Kyriakides S, Ohno S, Llorca PF, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-220.

Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming Burden of Triple-Negative Breast Cancer in India. Clin Breast Cancer. 2018;18(3):393-9.

He L, Lv Y, Song Y, Zhang B. The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity. Cancer Manag Res. 2019;11:5765-75.

Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017;8(17):27990-6.

Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003;78(1):105-18.

Chiu JH, Wen CS, Wang JY, Hsu CY, Tsai YF, Hung SC, et al. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers. J Transl Med. 2017;15(1):97.

Arciero CA, Guo Y, Jiang R, Behera M, Regan OR, Peng L, et al. ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer. Clin Breast Cancer. 2019;19(4):236-45.

Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019;121(12):991-1000.

Jones LB. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009;27(31):5278-86.

Kunikullaya SU, Poddar J, Sharma AD, Patel S. Pattern of distant metastasis in molecular subtypes of carcinoma breast: An institutional study. Indian J Cancer. 2017;54(1):327-32.

Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012;21(1):50-7.

Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108-14.

Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, et al. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncol. 2017;3(5):666-71.